Seelos therapeutics announces a strategic device partnership with aptargroup, inc.

New york, april 6, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (cns) disorders and rare diseases, announced today the signing of an agreement between seelos and aptargroup, inc. (nyse: atr) for the co-exclusive use and supply of aptar pharma's bidose (bds) liquid system device for seelos' intranasal ketamine product candidate, sls-002, in the investigational development programs for the treatment of suicidality, depression, and post-traumatic stress disorder (ptsd). under the terms of the agreement, seelos has certain rights to add other undisclosed indications to the strategic device partnership.
SEEL Ratings Summary
SEEL Quant Ranking